Editas Medicine (EDIT) Misses Q2 EPS by 12c
Tweet
Share
E-mail
Get Alerts EDIT Hot Sheet
Join SI Premium – FREE
Editas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.82), $0.12 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $510 thousand versus the consensus estimate of $4.78 million.
For earnings history and earnings-related data on Editas Medicine (EDIT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
- Bernstein SocGen Group Reiterates Outperform Rating on UnitedHealth Group (UNH)
- Lockheed Martin bids for NATO modeling and simulation contract
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
